[{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Fluasterone","moa":"NFkB","graph1":"Endocrinology","graph2":"Phase II","graph3":"SteroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SteroTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"SteroTherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"MMP-13","graph1":"Oncology","graph2":"Undisclosed","graph3":"SteroTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SteroTherapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"SteroTherapeutics \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ST-002","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"SteroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SteroTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SteroTherapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by SteroTherapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : ST-002 is a glucocorticoid receptor antagonist, small molecule drug candidate which is currently being evaluated for the treatment of cushing's syndrome.

                          Product Name : ST-002

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 24, 2025

                          Lead Product(s) : ST-002

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The licensed compounds are highly selective matrix metalloproteinase 13 (MMP-13) inhibitors that display robust modulation of osteoclastogenesis with excellent solubility and stability that portend to be highly effective add-on treatments to the current ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 30, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Moffitt Cancer Center

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : SteroTherapeutics will provide the study drug (non-androgenic analogue of dehydroepiandrosterone) and placebo to enable the NICHD to conduct the Phase 2 clinical trial in the treatment of the manifestations of Cushing syndrome.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          February 12, 2020

                          Lead Product(s) : Fluasterone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : National Institutes of Health

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank